Orexigen Therapeutics Inc

Orexigen Therapeutics — Investor Presentation (December 2010)

25 slides from Orexigen Therapeutics's investor presentation, Dec 17, 2010

  1. Slide 1: Investor Presentation, December 2010

    Investor Presentation Investor Presentation December 2010 December 2010 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “assuming” and similar expressions are intended to identify forwa

  3. Slide 3: Realizing the Vision: Industry Leader in Obesity Therapeutics

    Realizing the Vision Industry Leader in Obesity Therapeutics PRODUCTS Contrave ® – NDA under review by FDA Empatic™ – Preparing for Phase III STRATEGY/EXECUTION Successful Execution on All Major Milestones to Date Gain High Quality Partners for Global Commercialization RESOURCES Powerful Partner for

  4. Slide 4: 2010 – A Year of Strong Execution

    2010 – A Year of Strong Execution 2010 – A Year of Strong Execution Q1 Q2 Q3 Q4 Filed NDA NDA Accepted by FDA Clinical Results Published in The Lancet and Obesity Signed Takeda Partnership Positive Advisory Committee Meeting

  5. Slide 5: Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm

    Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm Increase in Obesity 16% 34% 43% Serious Disease Attributable to Obesity Treatment Options Needed Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm Source: http://www.cdc.gov; http://www.fightchronicdisease.org; F

  6. Slide 6: Slide 6

  7. Slide 7: Key Results from Advisory Committee

    Key Results from Advisory Committee 13:7 on Approvability 11:8 – Outcomes Trial should be Run Post-Approval (Not Pre-approval) Major Takeaways Key Results from Advisory Committee Efficacy Met FDA Guidance Strong Support for Comprehensive Risk Mitigation Strategy Desire for a Post-Approval Outcomes S

  8. Slide 8: Typical Response to Weight Loss Therapy is not Uniform

    Typical Response to Weight Loss Therapy is not Uniform COR-I Weight Loss Distribution (Contrave32) -40 -30 -20 -10 Typical Response to Weight Loss Therapy is not Uniform

  9. Slide 9: Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response

    Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response COR-I Weight Loss Distribution (Contrave32) -40 -30 -20 -10 Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response Our Focus: Patients Who Lose 5% <5% weight loss

  10. Slide 10: Slide 10

  11. Slide 11: Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss

    Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss Weight Loss Distribution 0% - 5% Weight loss 10% - 15% Weight Loss Avg Wt Loss = 26.7 lbs >15% Wt Loss Avg Wt Loss = 43.9 lbs Weight Gain 5% - 10% Weight Loss Avg Wt Loss = 17.0 lbs Contrave Early Responders Go on to Achiev

  12. Slide 12: Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters

    Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Contrave32 N=1038 Proportion w/ 5% Wt Loss Wk 16 Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Improvement (Standardized Mean Change from Baseline) Contrave32 N=1038 Placebo N=254

  13. Slide 13: Contrave: Well Characterized Safety Profile

    Contrave: Well Characterized Safety Profile Delivers Safety Experience Consistent with 20+ Year History of Underlying Agents Known Areas of Focus – CV Effects, Seizure, Psychiatric Effects, Creatinine Meets FDA Guidance for Patient Exposure for Evaluation of Safety and Tolerability with >4,500 Patie

  14. Slide 14: Slide 14

  15. Slide 15: Post-approval Outcomes Trial Represents Significant Opportunity for Orexigen

    Post-approval Outcomes Trial Represents Significant Opportunity for Orexigen Beneficial outcomes predicted based on cardiometabolic improvements -- Demonstrating outcomes benefit could be transformational for Contrave and the obesity field Proposing large simple trial (LST) -- Streamlined, practical

  16. Slide 16: Takeda Is the Ideal Partner for Contrave

    Takeda Is the Ideal Partner for Contrave SCALE Top 15 Pharma Significant U.S. Presence Primary Care Focus COMMITMENT TO OBESITY Partnership with Amylin Stated Strategy DOMAIN EXPERTISE Leader in Cardiometabolic Care Excellence in Life Cycle Management POWERFUL BRAND BUILDER Actos ~$3B in U.S. Sales

  17. Slide 17: Competitive Product Profile Attractive to Patients

    Competitive Product Profile Attractive to Patients Women Dominate the Market 1/3 to 1/2 Experienced Market-Meaningful Weight Loss No Addictive Concerns 73% Competitive Product Profile Attractive to Patients % of Patients Losing 10% of Body Weight after Completing 1 year of Treatment Avg Loss 34 lbs

  18. Slide 18: Contrave: Keys to Commercial Success

    Contrave: Keys to Commercial Success Blockbuster Market Size Market Growth Significant Unmet Need – Limited Competition Diet & Lifestyle Modifications Contrave: Differentiated Profile Takeda: Heavily Resourced Contrave: Keys to Commercial Success Source: CDC (2009) 103M US Obesity Rate Growth Obesit

  19. Slide 19: We Partnered Early for the Significant Activities Required for a Quality Launch

    We Partnered Early for the Significant Activities Required for a Quality Launch Sales Force Professional Patient Brand Development Market Development Managed Markets; Government Affairs We Partnered Early for the Significant Activities Required for a Quality Launch Sales Aids Direct Mail Physician E

  20. Slide 20: PHI

    PHI

  21. Slide 21: Empatic: Second Late Stage Obesity Program with Complementary Profile

    Empatic: Second Late Stage Obesity Program with Complementary Profile Empatic: Second Late Stage Obesity Program with Complementary Profile Observed Case Analysis Key to Multi-Solution Approach - High Efficacy - Different MOA than Contrave - Helps Orexigen Meet Differing Patients Needs Safety Profil

  22. Slide 22: —_>—sFZ/

    —_>—sFZ/

  23. Slide 23: No Foreseeable Need to Finance

    No Foreseeable Need to Finance Strong Balance Sheet Near-Term Milestones Low Burn Rate No Foreseeable Need to Finance $50M Payment from Takeda in Q3 $100M of Cash and Investments as of 9/30/10 $100M in Milestones Achievable Between Now and Product Launch Additional Milestones for New Potential Colla

  24. Slide 24: Realizing the Vision: Industry Leader in Obesity Therapeutics

    Realizing the Vision Industry Leader in Obesity Therapeutics PRODUCTS Contrave ® - NDA under review by FDA Empatic™ – Preparing for Phase III STRATEGY/EXECUTION Successful Execution on All Major Milestones to Date Gain High Quality Partners for Global Commercialization RESOURCES Powerful Partner for

  25. Slide 25: Slide 25

Orexigen Therapeutics — Investor Presentation (December 2010) on 6ix